Expert consensus of anti-tumor drugs prescription review: kidney cancer
- VernacularTitle:抗肿瘤药物处方审核专家共识：肾癌
- Author:
Min LIU
1
;
Wei MIAO
;
Chao ZHANG
;
Jie ZHANG
;
Yuanyuan DAI
;
Mei DONG
;
Jiang LIU
;
Hongbing HUANG
;
Qing ZHAI
;
Yuguo LIU
;
Ting XU
;
Ping HUANG
;
Wenzhou ZHANG
;
Gang JIANG
;
Junling CAO
;
Lixia WANG
;
Yancai SUN
;
Mingyan JIANG
;
Yongning LYU
;
Xiaoyang LU
;
Maobai LIU
;
Ningsheng LIANG
;
Zhu DAI
;
Yanqing SONG
;
Pengmei LI
;
Guangxuan LIU
;
Zhiying HAO
;
Dunwu YAO
;
Guiru LI
;
Shujia KONG
;
Ruixiang XIE
;
Jianhua WANG
;
Qing WEI
;
Lechuan JIA
;
Mei LI
;
Jun MENG
;
Fang CAO
;
Hongzhe SHI
;
Dan YAN
;
Zaixian BAI
;
Chen WANG
;
Guohui LI
;
Jie HE
Author Information
- Publication Type:Journal Article
- Keywords: Carcinoma, renal cell; Drug prescriptions; Practice guideline
- From: Adverse Drug Reactions Journal 2021;23(6):285-292
- CountryChina
- Language:Chinese
- Abstract: Kidney cancer usually requires multidisciplinary individualized treatments. No matter what kind of treatment, drugs are essential. According to the "six-step process" (prescription legitimacy review, patient basic information evaluation review, treatment protocol review, organ function and laboratory index review, pretreatment review, and unconventional prescription review) in prescription review proposed by the anti-tumor drug prescription review expert group and referring to domestic and foreign kidney cancer guidelines and drug instructions in recent years, this consensus selects 9 targeted drugs and 4 immunotherapeutic drugs that are currently commonly used in China and elaborates the key review points in patient basic information evaluation review, treatment protocol review, and organ function and laboratory index review of kidney cancer drug treatment, in order to provide reference for clinical front-line pharmacists to review prescriptions of kidney cancer patients and promote rational drug use in clinic.
